Viking, Structure, Terns Benefitting From Disappointing Novo Nordisk Weight Loss Data
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill -- WSJ
Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
New Dimensions in Pavement Markings Successfully Acquired by Strategic Buyer
What the Options Market Tells Us About Viking Therapeutics
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 45.2%
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Viking Therapeutics(VKTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.4% and a total average return of 24.3%
Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
BTIG analyst Justin Zelin maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 40.2% and a
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Morgan Stanley analyst Michael Ulz maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 41.0
Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
viking therapeutics (VKTX.US) rose over 11% on Wednesday! Received a 'shareholding' rating from Morgan Stanley.
Morgan Stanley gives Viking Therapeutics a "shareholding" rating with a target price of $80 and includes the stock on its watchlist.